Menu
Back to User profile » Dr Anna Forsythe
Papers published by Dr Anna Forsythe:
Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR)
Musat MG, Kwon CS, Masters E, Sikirica S, Pijush DB, Forsythe A
ClinicoEconomics and Outcomes Research 2022, 14:35-48
Published Date: 10 January 2022
What Does the Economic Burden of Acute Myeloid Leukemia Treatment Look Like for the Next Decade? An Analysis of Key Findings, Challenges and Recommendations
Forsythe A, Sandman KE
Journal of Blood Medicine 2021, 12:245-255
Published Date: 5 May 2021
Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews
Lee LJ, Kwon CS, Forsythe A, Mamolo CM, Masters ET, Jacobs IA
ClinicoEconomics and Outcomes Research 2020, 12:693-709
Published Date: 23 November 2020
Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States
Tremblay G, Said Q, Roy AN, Cai B, Ashton Garib S, Hearnden J, Forsythe A
ClinicoEconomics and Outcomes Research 2019, 11:673-681
Published Date: 12 November 2019
Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons
Tremblay G, Westley T, Cappelleri JC, Arondekar B, Chan G, Bell TJ, Briggs A
ClinicoEconomics and Outcomes Research 2019, 11:551-565
Published Date: 6 September 2019
Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review
Forsythe A, Kwon CS, Bell T, Smith TA, Arondekar B
ClinicoEconomics and Outcomes Research 2019, 11:87-98
Published Date: 14 January 2019
Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer
Tremblay G, Chandiwana D, Dolph M, Hearnden J, Forsythe A, Monaco M
Cancer Management and Research 2018, 10:1319-1327
Published Date: 22 May 2018
Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2– metastatic breast cancer
Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Tremblay G
Breast Cancer: Targets and Therapy 2018, 10:69-78
Published Date: 4 May 2018
Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?
Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Shor A, Tremblay G
Cancer Management and Research 2018, 10:1015-1025
Published Date: 4 May 2018
Systematic review of health state utility values for acute myeloid leukemia
Forsythe A, Brandt PS, Dolph M, Patel S, Rabe APJ, Tremblay G
ClinicoEconomics and Outcomes Research 2018, 10:83-92
Published Date: 25 January 2018